Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002259 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma
A Phase 2 study, sponsored by Lederle Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002259: Completed Phase 2 study, sponsored by Lederle Laboratories.
NCT00002259 is a Phase 2 study that has completed, run by Lederle Laboratories. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002259, a Phase 2 study, has completed, sponsored by Lederle Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
Interventions
- DRUG Mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00002259 record still lists
NCT00002259 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Mitoxantrone hydrochloride is the first listed.
NCT00002259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002259 about?
NCT00002259 is a clinical study titled "Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma". To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
What is the current status of trial NCT00002259?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002259?
The interventions under investigation include: Mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002259?
This trial is sponsored by Lederle Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.